$CODX

Abbott Richard David sold (to issuer) $3K of CODX

Abbott Richard David (President) sold (to issuer) 680 shares of Co-Diagnostics, Inc. (CODX) at $5.07 on 2026-05-23.

Original reporting
SEC EDGAR · Abbott Richard David
Published May 27, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CODX
Neutral
high confidence
Mentioned
$CODX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CODXNeutralLow
01

Why it matters

The filing documents an officer/direct sale to the issuer (680 shares) at $5.07 with holdings after the trade of 3,417 shares; it does not include any business update.

02

Market read

Primarily a sentiment/ownership-visibility datapoint; no fundamental catalyst is described.

03

What to watch

No 10b5-1 plan is disclosed, but the transaction is small; without additional insider activity or company fundamentals, signal-to-noise is low.

Relevance 3/10Timing: Immediate but likely limited; Form 4 updates can affect very short-term sentiment only.

Background

The article is an SEC Form 4 insider transaction disclosure for Co-Diagnostics, Inc. (CODX).

Company-level read

Ticker impact

$CODXNeutralHigh confidence
Context

Co-Diagnostics officer Richard David Abbott sold 680 shares to the issuer at $5.07 via a Form 4, changing insider ownership visibility.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment/flow effects rather than a thesis change.

Evidence & confidence

Form 4 insider transactions are common and the filing provides no accompanying operational or financial catalyst; the disclosed size ($3.4k) is modest versus typical market moves.

Market effects

Minimal; no read-across catalyst (no trial, contract, or regulatory action) is provided.

None indicated.

None indicated.

Counterpoint

The sale-to-issuer code (D) can reflect administrative liquidity or buyback participation rather than bearish intent, so price impact may be overstated.

Key entities

  • Co-Diagnostics, Inc.

    Subject of the Form 4 insider transaction; officer Richard David Abbott sold 680 shares to the issuer.

  • Abbott Richard David

    President of Co-Diagnostics; reported sale to issuer on 2026-05-23.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CODXMed

CoSara submits tuberculosis test for India regulatory review

Co-Diagnostics' India joint venture, CoSara, submitted its tuberculosis test for regulatory review in India, reporting 97.3% sensitivity and 96.0% specificity. The test, using Co-Diagnostics' technology, aims for approval by Q4 2026 to begin sales in India and South Asia. India has the highest tuberculosis burden globally, according to the WHO.

$CODXMedAI 8/10

Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India

Co-Diagnostics' joint venture CoSara Diagnostics completed a clinical study for its tuberculosis test, reporting 97.3% sensitivity and 96.0% specificity. The test was submitted to India's CDSCO for regulatory clearance, with a commercial launch anticipated before year-end 2026. The company has also deployed mobile and cloud infrastructure in India to support the launch.

$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.